Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
- Terminas
- 2027-09-16
- Atidaryta
- 2027-02-10
- Biudžetas
- 115 323 812 €
- Tipas
- grant
Aprašymas
Expected Outcome:Proposals under this topic should aim to deliver results that are directed and tailored towards, and contribute to all of the following expected outcomes:Patients with rare or very rare cancers or cancer subtypes have access to tailored, promising biomarker-guided medicines or multi-modal treatment interventions via participation in subsequent clinical trials or national or regional compassionate use programmes by health authorities;Researchers, physicians, innovators[1], startup, spin-off and spin-out companies, SMEs, charities or foundations and other professionals from different disciplines and sectors have access to innovative technology, medical devices or promising biomarker-guided medicines for further validation or commercialisation;National healthcare providers, policymakers and authorities in European regions, EU Member States and Associated Countries have early safety and efficacy evidence to support further testing of affordable biomarker-guided medicines or multi-modal treatment interventions that benefit patients with rare or very rare cancers in their healthcare systems; Scope:Patients with rare and very rare[2] cancers across EU Member States and Associated Countries often present with advanced disease due to late diagnosis and have access to few treatment options. Hence, these patients typically have a lower 5-year overall survival than those with more common cancers and face challenges with timely access to a small number of appropriate phas
Tinkamumas (iš šaltinio)
General conditions1. Admissibility conditions: Proposal page limit and layoutdescribed in Annex A and Annex E of the Horizon Europe Work Programme General Annexes.Proposal page limits and layout: described in Part B of the Application Form available in the Submission System.2. Eligible countriesdescribed in Annex B of the Work Programme General Annexes.A number of non-EU/non-Associated Countries that are not automatically eligible for funding have made specific provisions for making funding available for their participants in Horizon Europe projects. See the information in the Horizon Europe Programme Guide.3. Other Eligibility Conditionsdescribed in Annex B of the Work Programme General Annexes.4. Financial and operational capacity and exclusiondescribed in Annex C of the Work Programme General Annexes.5a. Evaluation and award: Award criteria, scoring and thresholdsdescribed in Annex D of the Work Programme General Annexes.5b. Evaluation and award: Submission and evaluation processesThe thresholds for each criterion will be 4 (Excellence), 4 (Impact) and 4 (Implementation). The cumulative threshold is 12.described in Annex F of the Work Programme General Annexes and the Online Manual.5c. Evaluation and award: Indicative timeline for evaluation and grant agreementdescribed in Annex F of the Work Programme General Annexes.6. Legal and financial set-up of the grantsEligible costs will take the form of a lump sum as defined in the Decision of 7 July 2021 authorising the use of lump sum contributions under the Horizon Europe Programme – the Framework Programme for Research and Innovation (2021-2027) – and in actions under the Research and Training Programme of the European Atomic Energy Community (2021-2025) [[This decision is available on the Funding and Tenders Portal, in the reference documents section for Horizon Europe, under ‘Simplified costs decisions’ or through this link: https://ec.europa.eu/info/funding-tenders/opportunities/docs/2021-2027/horizon/guidance/ls-decision_he_en.pdf]].The granting authority may, up to 4 years after the end of the action, object to a transfer of ownership or to the exclusive licensing of results, as set out in the specific provision of Annex 5.described in Annex G of the Work Programme General Annexes.Specific conditions described in the specific topic of the Work Programme Application and evaluation forms and model grant agreement (MGA): Application form templatesPlease use the application form that you will find in the Submission System. You can find examples of standard application forms in the Reference Documents page.Evaluation form templates — will be used with the necessary adaptationsStandard evaluation form (HE RIA, IA) GuidanceHE Programme Guide Model Grant Agreements (MGA)Lump Sum MGA Call-specific instructions Detailed budget table (HE LS) Information on clinical studies (HE) Guidance: "Lump sums - what do I need to know?"Additional documents: HE Main Work Programme 2026-2027 – 1. General Introducti
Ar šis kvietimas tinka jūsų organizacijai?
Nariams — automatinis tinkamumo vertinimas pagal jūsų profilį, raktažodžių paieška, filtrai, stebėjimo sąrašas ir pranešimai apie naujus panašius kvietimus.